Simeprevir: A novice treatment option for chronic hepatitis C infection
T Rajeev Kumar, B Gopi Krishna, S Yashita Raga, SVS Gopi Raju, Syed Fathima and G Radhika
Imeprevir (TMC435, Olysio™), a second-generation hepatitis C virus (HCV) PI, has been recently approved for the treatment of genotype 1 chronic hepatitis C together with pegylated interferon and ribavirin. This molecule has very different characteristics from first-generation protease inhibitors. Results from trials show that simeprevir is very effective and safe, with few adverse events. We discuss the precise features of this new treatment option for HCV infection, in terms of in vitro data, pharmacological data, and clinical trials. We also discuss the impact of Q80K polymorphism at baseline. Studies evaluating interferon-free regimens with simeprevir are ongoing. Future combinations of two or more direct-acting antiviral agents, targeting different viral enzymes and with synergistic antiviral effects, are going to be approved, allowing treatment of pan-genotypic HCV with optimized sustained virologic responses. Simeprevir will undoubtedly be a part of future treatment strategies.
How to cite this article:
T Rajeev Kumar, B Gopi Krishna, S Yashita Raga, SVS Gopi Raju, Syed Fathima, G Radhika. Simeprevir: A novice treatment option for chronic hepatitis C infection. Pharma Innovation 2020;9(4):01-03.